Victor Gonzalez, MD
Retina Specialist · McAllen, TXNPI 1871599100
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (45.1%), other and speaking fees — rather than concentrated in one kind of arrangement. 58 manufacturers reported payments, led by US Retina LLC at 32.5% of the total. Reporting peaked in 2021 at $81,013 and has fallen 77.7% since, to $18,052 in 2025. Among retina specialist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 648 payments — averaging $516.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- US Retina LLC$109K
- Bausch & Lomb Americas Inc.$40K
- Beaver-visitec International, Inc.$29K
- Bausch & Lomb, A Division Of Bausch Health US, LLC$25K
- Alimera Sciences, Inc.$18K
- AbbVie$17K
- plus $97K from 52 others
Across 265 payments — averaging $6824.48 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$592K
- Genentech, Inc.$311K
- Boehringer Ingelheim International GmbH$129K
- Regeneron$113K
- Astellas Pharma Global Development$109K
- Apellis Pharmaceuticals, Inc.$103K
- plus $451K from 17 others
What the payments were for
- Consulting fees$151,00145%
- Speaking & faculty fees$34,71510%
- Travel & lodging$7,6392%
- Food & beverage$32,34110%
- Gifts$190%
- Entertainment$770%
- Ownership interest$26,5308%
- Other$82,40825%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- STELLARIS$37,742
- OPHTHALMIC INSTRUMENTS$24,298
- EYLEA$20,480
- Iluvien$17,347
- XIPERE$14,476
- Lucentis$13,444
- OZURDEX$12,084
- Bausch + Lomb$9,325
- RTH258A_BEOVU_OPHTHALMOLOGY$8,624
- VITESSE$7,377
- IHEEZO$6,104
- Syfovre$6,018
- TRIESENCE$5,600
- STELLARIS PC$4,500
- CRYSTALENS$4,500
- VABYSMO$4,338
- VISUDYNE$2,250
- RETISERT$2,250
- YUTIQ$2,163
- BEOVU$2,160
How this compares
$334,731 in reported general payments places this provider in the 95th percentile of 108 retina specialist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CombiganBrimonidine Tartrate/Timolol | 160 | $66,309 |
| Ketorolac Tromethamine | 1,479 | $46,910 |
| Prednisolone Acetate | 893 | $44,607 |
| LumiganBimatoprost | 71 | $38,267 |
| RestasisCyclosporine | 45 | $32,770 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 154 | $29,596 |
| ProlensaBromfenac Sodium | 63 | $23,653 |
| VyzultaLatanoprostene Bunod | 34 | $13,814 |
| XiidraLifitegrast | 12 | $12,675 |
| Loteprednol Etabonate | 66 | $10,650 |
| Bromfenac Sodium | 57 | $10,178 |
| Cyclosporine | 18 | $10,142 |
| MoxifloxacinMoxifloxacin Hcl | 360 | $10,100 |
| RhopressaNetarsudil Mesylate | 26 | $9,643 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 36 | $9,295 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieCombigan, Lumigan, Restasis | $16,533 | $137,346276 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate | $25,442 | $34,303129 claims |
| Bausch & Lomb Americas Inc.Vyzulta, Xiidra | $39,934 | $26,48946 claims |
| Aerie Pharmaceuticals, Inc.Rhopressa | $89 | $9,64326 claims |
| AlconSimbrinza | $2,869 | $9,29536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 108 retina specialist providers in Texas.
Other retina specialist in McAllen
- Nehal PatelMcAllen$7K
- Courtney CrawfordBurleson$342K
- Jeremiah BrownSchertz$339K
- Judy KimDallas$256K
- Emmanuel ChangBellaire$254K
- Ting Fang SuarezBellaire$156K
- Hemang PandyaPlano$153K
- Margaret RunnerSouthlake$71K
- Moises ChicaSan Antonio$43K
- Garvin DavisHouston$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.